George Scangos, Biogen

CEO, Biogen
Total 2014 Compensation: $18.63 million

Biogen ($BIIB) has been on a growth streak, fueled by its multiple sclerosis hotshot pill Tecfidera. It recently rolled out two next-gen hemophilia drugs. And it has whetted investors' appetite with early-stage results for an Alzheimer's drug that--if successful, and that's a big if--could zoom to $5 billion in peak sales. The company is so jazzed about its pipeline that it's building a $1 billion plant in Switzerland and figures it will need more manufacturing capacity to keep up.

CEO George Scangos has watched his pay grow, too. Scangos totted up $18.6 million for 2014, up from $15 million in 2013 and $13.45 million the year before that.

Scangos' compensation is heavily weighted toward equity, but he has collected sizable cash incentive pay, too. His base salary was a run-of-the-mill $1.38 million for 2014--on par with that of many other biopharma chiefs--but his incentive pay was on the higher end of things at $4.05 million.

Perhaps that's because Biogen doesn't hand out options. Scangos' equity compensation was all on the stock-award side at $12.12 million. $90,000 in pension benefits and $1 million in other compensation round out the total.

For more:
Special Reports: 15 Highest-Paid Biopharma CEOs of 2013 - George Scangos, Biogen Idec | The 25 most influential people in biopharma today - George Scangos
Biogen to build $1B plant, add 400 jobs in Switzerland
Which Big Biotechs join Gilead in Fortune's fastest-growing pharma ranks?
Biogen's hot MS meds could push Pfizer off its CNS throne
Back-to-'Biogen' shift signals wider industry branding trend
Move over, Big Pharma: Smaller biopharma's execs are bringing home more bacon

George Scangos, Biogen
Read more on

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity